deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00936858

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Sponsor: Dana-Farber Cancer Institute

Conditions Thyroid Cancer
Interventions RAD001
Updated 11 times since 2017 Last updated: Oct 1, 2021 Started: Jul 31, 2009 Primary completion: Feb 27, 2020 Completion: Feb 27, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Thyroid Cancer and is currently completed. Dana-Farber Cancer Institute leads this study, which shows 11 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshotActive Not Recruiting~Mar 2019 – ~Nov 2019 · 8 months · monthly snapshotActive Not Recruiting~Nov 2019 – ~Apr 2020 · 5 months · monthly snapshotActive Not Recruiting~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshotCompleted~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotCompleted~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshotCompleted~Nov 2021 – ~Jul 2024 · 32 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Nov 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Oct 2021 — Nov 2021 [monthly]

    Completed PHASE2

  5. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE2

▶ Show 6 earlier versions

  1. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Nov 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  3. Mar 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • M.D. Anderson Cancer Center
  • MOUNT SINAI HOSPITAL
  • Massachusetts General Hospital
  • Novartis
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations